Articles

Share this:
Email

Like this page on Facebook

Breast Cancer Subtype Dream Team (Dream Team Series Part 3 of 5)

by SU2C

Filed under | Breast Cancer

We used to think there was only one type of breast tumor. But that’s not the case. There are actually three different subtypes of breast cancer: ER-positive, HER2-positive, and triple negative. And they don’t all respond to the same cancer drugs. There is, however, a trait that all three types of tumors share: they can learn how to “outsmart” treatments that are initially effective, and again start growing uncontrollably.

This problem, called treatment resistance, is one of the biggest obstacles to curing breast cancer. But if anyone can surmount it, it’s our Breast Cancer Subtype Dream Team. Led by Joe W. Gray, Ph.D., and Dennis J. Slamon, M.D., Ph.D., this Dream Team is developing new drugs and identifying new drug targets that tumors will have a hard time outsmarting.

They also are building a comprehensive breast cancer research database that researchers can use to quickly and easily gain information about past study findings and promising new targets. “The goal,” says Gray, “is literally to flip a switch and make it available to the entire world.”

Adds Slamon, “We’re hoping that this effort will really change the paradigm.” As we make progress, we intend to make it visible and palpable to the public. “And there is no question in my mind that is going to happen.”

Watch the video below to learn more about the Breast Cancer Subtype Dream Team’s research.

Return to Music and Comedy

For updates on the science that SI2C funds, please register at SU2C.org
A one percent reduction in cancer deaths would be worth $500 billion, almost 2.5 times what the U.S. spends each year on the disease.